HENRY E. WILSON, M.D., F.A.C.P.; JOHN LOUIS, M.D., F.A.C.P.
Early studies by the Midwest Cooperative Chemotherapy Group to determine the therapeutic spectrum for parenteral vinblastine sulfate1 indicated that Hodgkin's disease was the most responsive tumor (1).
The obvious advantages of an effective oral route of administration and the knowledge that there is significant gastrointestinal absorption of vinblastine sulfate have made it desirable to define the optimal limits of oral dosage. Earlier comparative studies of the oral and parenteral routes of administration suggested that responses could be obtained by the orally administered drug in doses two to three times that of the intravenous dose. However, the wide variation in dosage
WILSON HE, LOUIS J. The Response of Hodgkin's Disease to Treatment with Oral Vinblastine Sulfate. Ann Intern Med. ;67:303–308. doi: 10.7326/0003-4819-67-2-303
Download citation file:
Published: Ann Intern Med. 1967;67(2):303-308.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use